STAT examines the policy debate over concentrated 7-OH products

Why it matters

The report captures a central policy question for clinicians, people who use kratom products, and regulators: how to address concentrated 7-OH products while distinguishing them from traditional kratom leaf products.

The big picture

Kratom leaf products have been sold in the United States for decades with limited federal restrictions. The report says newer products containing the semi-synthetic derivative 7-hydroxymitragynine, or 7-OH, have prompted concern about dependence and have sharpened disagreement over the appropriate regulatory response.

Key findings

• The report identifies concentrated 7-OH products as a growing concern distinct from traditional kratom leaf products.
• Clinicians and recovery advocates cited potential dependence risks from highly concentrated 7-OH, while noting that research remains limited.
• The DEA proposed temporary Schedule I controls for 7-OH above a specified potency threshold in July.
• The proposed approach would leave lower-potency natural kratom products outside that temporary control.
• Stakeholders broadly favor guardrails but disagree over the form regulation should take.

What they say

STAT reports that experts and users generally agree some guardrails are needed, but remain divided over how concentrated 7-OH and kratom products should be regulated.

Bottom line

The policy debate is increasingly focused on whether potency-based controls can address concentrated 7-OH risks without treating all kratom products the same.